Home > Insider Trading > Filing (0000899243-19-010492)

Filing Details

Accession Number:: 0000899243-19-010492
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-04-10 19:21:59
Reporting Period:: 2019-04-08

Accepted Time:: 2019-04-10 19:21:59
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1348911	Kalvista Pharmaceuticals Inc.	KALV	Pharmaceutical Preparations (2834)	200915291

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1367381	Sv Life Sciences Fund Iv, L.p.	One Boston Place 201 Washington Street, Suite 3900 Boston MA 02108	No	No	Yes	No
1392309	Sv Life Sciences Fund Iv Strategic Partners, L. P.	One Boston Place 201 Washington Street, Suite 3900 Boston MA 02108	No	No	Yes	No
1422339	Svlsf Iv, Llc	One Boston Place 201 Washington Street, Suite 3900 Boston MA 02108	No	No	Yes	No
1422340	Sv Life Sciences Fund Iv (Gp), L.p.	One Boston Place 201 Washington Street, Suite 3900 Boston MA 02108	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2019-04-08	22,171	$29.49	1,698,554	No	4	S	Direct
Common Stock	Disposition	2019-04-08	629	$29.49	48,222	No	4	S	Direct
Common Stock	Disposition	2019-04-09	13,292	$28.53	1,685,262	No	4	S	Direct
Common Stock	Disposition	2019-04-09	377	$28.53	47,845	No	4	S	Direct
Common Stock	Disposition	2019-04-10	13,157	$29.40	1,672,105	No	4	S	Direct
Common Stock	Disposition	2019-04-10	374	$29.40	47,471	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.13 to $30.08, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
These shares are held directly by SVLS IV LP.
SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein.
These shares are held directly by Strategic Partners.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.02 to $29.685, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.07 to $29.71, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.